<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0902200010
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SKYRIZI 75 mg 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISANKIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13774.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AbbVie Deutschland GmbH &amp; Co KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AbbVie Deutschland GmbH & Co KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Skyrizi contains the active substance risankizumab.</p><p>Skyrizi is used to treat the following inflammatory diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plaque psoriasis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic arthritis</p><p>&nbsp;</p><p><strong>How Skyrizi works</strong></p><p>This medicine works by stopping a protein in the body called &lsquo;IL-23&rsquo;, which causes inflammation.</p><p><u>&nbsp;</u></p><p><u>Plaque psoriasis</u></p><p>Skyrizi is used to treat adults with moderate to severe plaque psoriasis. Skyrizi reduces inflammation and can therefore help reduce symptoms of plaque psoriasis such as burning, itching, pain, redness, and scaling.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Psoriatic arthritis</u></p><p>Skyrizi is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes inflamed joints and psoriasis. If you have active psoriatic arthritis, you may first be given other medicines. If these medicines do not work well enough, you will be given Skyrizi either alone or in combination with other medicines to treat your psoriatic arthritis.</p><p>&nbsp;</p><p>Skyrizi reduces inflammation and can therefore help to reduce pain, stiffness, and swelling in and around your joints, pain and stiffness in your spine, psoriatic skin rash, psoriatic nail damage, and it may slow down damage to the bone and cartilage in your joints. These effects can ease your normal daily activities, reduce tiredness, and improve your quality of life.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to risankizumab or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an infection, including active tuberculosis, which your doctor thinks is important.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before and during the use of Skyrizi:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you currently have an infection or if you have an infection that keeps coming back.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have tuberculosis (TB).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently received or plan to receive an immunisation (vaccine). You should not be given certain types of vaccines while using Skyrizi.</p><p>&nbsp;</p><p><u>A</u><u>llergic reactions</u></p><p>Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin, with a red rash or raised bumps</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Skyrizi is not recommended for children and adolescents under 18 years of age. This is because Skyrizi has not been studied in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Skyrizi</strong></p><p>Tell your doctor, pharmacist or nurse:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using, have recently used or might use any other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had or are going to have a vaccination. You should not be given certain types of vaccines while using Skyrizi.</p><p>&nbsp;</p><p>If you are not sure, talk to your doctor, pharmacist or nurse before and during the use of Skyrizi.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Pregnancy, contraception and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This is because it is not known how this medicine will affect the baby.</p><p>&nbsp;</p><p>If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi.</p><p>&nbsp;</p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Skyrizi is not likely to affect your driving and use of machines.</p><p>&nbsp;</p><p><strong>Skyrizi contains sorbitol and sodium</strong></p><p>This medicine contains 68&nbsp;mg sorbitol per 150&nbsp;mg dose.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 150&nbsp;mg dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>This medicine is given as 2 injections under your skin (called &lsquo;subcutaneous injections&rsquo;).&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>How much Skyrizi to use</strong></p><p>&nbsp;</p><p>The dose is 150&nbsp;mg given as two 75&nbsp;mg injections.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>How much?</strong></p></td><td style="vertical-align:top"><p><strong>When?</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1<sup>st</sup> dose</strong></p></td><td style="vertical-align:top"><p>150 mg (<strong>two </strong>75 mg injections)</p></td><td style="vertical-align:top"><p>When your doctor tells you</p></td></tr><tr><td style="vertical-align:top"><p><strong>2<sup>nd</sup> dose </strong></p></td><td style="vertical-align:top"><p>150 mg (<strong>two</strong> 75 mg injections)</p></td><td style="vertical-align:top"><p>4 weeks after 1<sup>st</sup> dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>Further doses</strong></p></td><td style="vertical-align:top"><p>150 mg (<strong>two</strong> 75 mg injections)</p></td><td style="vertical-align:top"><p>Every 12 weeks starting after 2<sup>nd</sup> dose</p></td></tr></tbody></table><p>&nbsp;</p><p>You and your doctor, pharmacist or nurse will decide if you should inject this medicine yourself. Do not inject yourself with this medicine unless you have been trained by your doctor, pharmacist or nurse. A caregiver may also give your injections after they have been trained.</p><p>&nbsp;</p><p><strong>Read section 7 &lsquo;Instructions for use&rsquo; at the end of this leaflet before injecting Skyrizi yourself.</strong></p><p>&nbsp;</p><p><strong>If you use more Skyrizi than you should</strong></p><p>If you have used more Skyrizi than you should or the dose has been given sooner than prescribed, talk to your doctor.&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to use Skyrizi</strong></p><p>If you forget to use Skyrizi, inject a dose as soon as you remember. Talk to your doctor if you are not sure what to do.</p><p>&nbsp;</p><p><strong>If you stop using Skyrizi</strong></p><p>Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Talk to your doctor or get medical help immediately if you have symptoms of a serious infection such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, flu-like symptoms, night sweats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired or short of breath, cough which will not go away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warm, red and painful skin, or a painful skin rash with blisters</p><p>Your doctor will decide if you can keep using Skyrizi.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Tell your doctor, pharmacist or nurse if you get any of the following side effects</p><p>&nbsp;</p><p><strong>Very common:</strong> may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infections with symptoms such as sore throat and stuffy nose</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal skin infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions (such as redness or pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small raised red bumps on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side<br />effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the syringe label and outer carton after &lsquo;EXP&rsquo;.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Keep the pre-filled syringes in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if the liquid is cloudy or contains flakes or large particles.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Skyrizi contains </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is risankizumab. Each pre-filled syringe contains 75&nbsp;mg of risankizumab in 0.83&nbsp;mL solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are disodium succinate hexahydrate, succinic acid, sorbitol, polysorbate 20 and water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		Skyrizi is a clear and colourless to slightly yellow liquid in a pre-filled syringe with needle guard. The liquid may contain tiny white or clear particles.
	
Each pack contains 2 pre-filled syringes and 2 alcohol pads.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AbbVie Deutschland GmbH &amp; Co. KG</p><p>Knollstrasse</p><p>67061 Ludwigshafen</p><p>Germany</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturers</strong></p><p>&nbsp;</p><p>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</p><p>Biberach an der Riss, 88397, Germany</p><p>&nbsp;</p><p>Batch releaser:</p><p>AbbVie S.r.l.</p><p>04011 Campoverde di Aprilia , (Latina) , Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		This leaflet was last revised in Febraury 2023
	
	
	To reporting of side effects

•	Saudi Arabia

The National Pharmacovigilance and Drug Safety Centre (NPC)
-	Fax: +966-11-205-7662
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/


•	Other GCC States:

-	Please contact the relevant competent authority.



Council of Arab Health Ministries 


This is a medicament

-	Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
-	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
-	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-	Do not by yourself interrupt the period of treatment prescribed for you.
-	Do not repeat the same prescription without consulting your doctor.
-	Keep all medicaments out of reach of children.
	

Council of Arab Health Ministers
Union of Arab Pharmacist


	
	

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سكاي ريزي على المادة الفعالة ريسانكيزوماب، وهي كابتة انتقائية للمناعة، مثبطة للانترليوكينات.</p><p dir="RTL">يستخدم سكاي ريزي لعلاج الأمراض الالتهابية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; الصدفية اللويحية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصدفية</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف يعمل سكاي ريزي</strong></p><p dir="RTL">يعمل هذا الدواء عن طريق إيقاف بروتين في الجسم يدعى &rsquo;إنترليوكين-٢٣، IL-23&lsquo;، وهو عبارة عن بروتين يسبب الالتهاب.&nbsp;</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الصدفية اللويحية</u></p><p dir="RTL">يستخدم سكاي ريزي لعلاج البالغين المصابين بالصدفية اللويحية المتوسطة إلى الشديدة. يقلل سكاي ريزي من الالتهاب وبالتالي<u> </u>يمكن أن يساعد في تقليل أعراض الصدفية اللويحية مثل الحرقة، الحكة، الألم ،الاحمرار والقشور.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التهاب المفاصل الصدفية</u></p><p dir="RTL">يستخدم سكاي ريزي لعلاج البالغين المصابين بالتهاب المفاصل الصدفي. التهاب المفاصل الصدفي هو مرض يسبب التهاب المفاصل والصدفية. إذا كنت تعاني من التهاب المفاصل الصدفي النشط ، فقد يتم إعطاؤك أدوية أخرى أولاً. إذا لم تعمل هذه الأدوية جيدا ًبشكل كاف ، فسيتم إعطاؤك سكاي ريزي إما بمفرده أو مع أدوية أخرى لعلاج التهاب المفاصل الصدفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقلل سكاي ريزي من الالتهاب وبالتالي يمكن أن يساعد في تقليل الألم، التصلب والتورم في المفاصل وما حولها، وكذلك الألم والتصلب في العمود الفقري ، والطفح الجلدي الصدفي ، وتلف الأظافر الصدفي ، وقد يبطئ تلف العظام والغضاريف في مفاصلك. هذه الآثار يمكن أن تسهل أنشطتك اليومية العادية ، وتقلل من التعب ، وتحسن جودة حياتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سكاي ريزي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية تجاه ريسانكيزوماب أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بحالة عدوى، بما في ذلك السلّ النشط، يعتقد طبيبك أنها مهمة.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى&nbsp; طبيبك، الصيدلاني أو الممرضة قبل وأثناء استعمال سكاي ريزي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا في الوقت الحاضر بحالة عدوى متكررة الحدوث.&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالسلّ.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تلقيت مؤخرا أو كنت تخطط لتلقي تمنيعا (لقاحا). يجب أن لا تُعطى أنواعا معينة من اللقاحات أثناء استعمال سكاي ريزي.</p><p>&nbsp;</p><p dir="RTL"><u>التفاعلات التحسسية</u></p><p dir="RTL">أخبر طبيبك أو اطلب مساعدة طبية على الفور إذا لاحظت أيا من علامات التفاعل التحسسي أثناء تلقّي سكاي ريزي مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس أو البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة جلدية شديدة، مع طفح أحمر أو تحاديب مرتفعة</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح باستعمال سكاي ريزي للأطفال والمراهقين الذين لم يبلغوا عمر ١٨ سنة. وهذا لأن سكاي ريزي لم يُدرس في هذه المجموعة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسكاي ريزي</strong></p><p dir="RTL">أخبر طبيبك، الصيدلاني أو الممرضة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل حالياً، استعملت مؤخّراً، أو قد تستعمل أي دواء آخر.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تلقيت مؤخرا أو ستتلقى لقاحا. يجب أن لا تُعطى أنواعا معينة من اللقاحات في أثناء استعمال سكاي ريزي.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدا، تحدّث إلى&nbsp; طبيبك، الصيدلاني أو الممرضة قبل وأثناء استعمال سكاي ريزي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل، منع الحمل والإرضاع</strong></p><p dir="RTL">إذا كنت حاملا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك قبل استعمال هذا الدواء. وهذا يرجع لعدم معرفة ما إذا كان هذا الدواء سيؤثر على الطفل.</p><p>&nbsp;</p><p dir="RTL">إذا كنت امرأة يمكنها الحمل، فيجب أن تستعملي وسيلة لمنع الحمل أثناء استعمالك لهذا الدواء لمدة ٢١ أسبوعا على الأقل بعد آخر جرعة تتلقينها من سكاي ريزي.</p><p>&nbsp;</p><p dir="RTL">تحدّثي إلى طبيبك إن كنت مرضعا أو إن كنت تخططين للإرضاع قبل استعمال هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآليات</strong></p><p dir="RTL">من غير المرجح أن يؤثر سكاي ريزي على قيادتك أو استعمالك للآليات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي سكاي ريزي على السوربيتول والصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ٦٨ ملغم من السوربيتول في كل جرعة قدرها ١٥٠ ملغم.</p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ ميلي مول من الصوديوم (٢٣ ملغ) في كل جرعة قدرها ١٥٠ ملغم، ولذا يمكن القول أنه &rsquo;خالي من الصوديوم&lsquo;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دوما ملتزما تماما بالطريقة التي أشار عليك بها طبيبك أو الصيدلاني. اسأل طبيبك أو الصيدلاني إذا لم تكن متأكدا.</p><p dir="RTL">يعطى هذا الدواء على شكل حقنتين تحت جلدك (وتدعى &rsquo;حقن تحت الجلد&lsquo;).&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي كمية سكاي ريزي التي يجب استخدامها</strong></p><p dir="RTL">مقدار الجرعة ١٥٠ ملغم وتعطى على شكل حقنتين مقدار كل منهما ٧٥ ملغم.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>ما الكمية؟</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>متى؟</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الأولى</strong></p></td><td style="vertical-align:top"><p dir="RTL">١٥٠ ملغم (حقنتان ٧٥ ملغم)</p></td><td style="vertical-align:top"><p dir="RTL">عندما يخبرك طبيبك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الثانية </strong></p></td><td style="vertical-align:top"><p dir="RTL">١٥٠ ملغم (حقنتان ٧٥ ملغم)</p></td><td style="vertical-align:top"><p dir="RTL">بعد مرور أربع أسابيع على تلقي الجرعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعات الإضافية</strong></p></td><td style="vertical-align:top"><p dir="RTL">١٥٠ ملغم (حقنتان ٧٥ ملغم)</p></td><td style="vertical-align:top"><p dir="RTL">كل ١٢ أسبوعا تبدأ بعد الجرعة الثانية</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">ستقرر أنت وطبيبك، الصيدلاني أو الممرضة ما إذا كنت ستحقن هذا الدواء بنفسك. لا تحقن نفسك بهذا الدواء إلا إذا تلقيت تدريبا من قبل طبيبك، الصيدلاني أو الممرضة. يمكن لمقدمي الرعاية أيضا إعطاء الحقن بعد أن يكونوا قد تلقوا التدريب.</p><p>&nbsp;</p><p dir="RTL"><strong>اقرأ القسم ٧ &rsquo;تعليمات الاستعمال&lsquo; في نهاية هذه النشرة قبل أن تحقن سكاي ريزي بنفسك.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>إذا استعملت سكاي ريزي أكثر مما يجب</strong></p><p dir="RTL">إذا استخدمت كمية أكبر مما ينبغي من سكاي ريزي، أو إذا تلقيت الجرعة بوقت أبكر مما يجب، تحدث إلى طبيبك.&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تستعمل سكاي ريزي</strong></p><p dir="RTL">إذا نسيت تلقي سكاي ريزي، عليك أن تحقن جرعة بمجرّد أن تتذكرها. اسأل طبيبك إذا لم تكن متأكدا مما يجب أن تفعله.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال سكاي ريزي</strong></p><p dir="RTL">لا تتوقف عن استعمال سكاي ريزي دون التحدّث إلى طبيبك أولا. قد تعود أعراضك للظهور إذا توقفت عن استعمال سكاي ريزي.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك، الصيدلاني أو الممرضة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة </strong></p><p dir="RTL">تحدّث إلى طبيبك أو احصل على مساعدة طبية فورية إذا ظهرت لديك أعراض حالة عدوى خطيرة مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، أعراض شبيهة بالانفلونزا، تعرّق ليليّ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب أو ضيق النفس، سعال لا يتراجع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سخونة أو احمرار الجلد، أو طفح جلدي مؤلم مترافق ببثور بداخلها سوائل</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك ما إذا كان استمرارك بتلقي سكاي ريزي ممكنا.</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى</strong></p><p dir="RTL">أخبر طبيبك، الصيدلاني أو الممرضة إذا أصبت بأيٍّ من التأثيرات الجانبية التالية</p><p dir="RTL"><strong>شائعة جدا:</strong> قد تصيب أكثر من ١ من ١٠ أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى في الجهاز التنفسي العلوي مع أعراض كاحتقان الحلق واحتقان الأنف</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> قد تصيب حتى ١ من ١٠ أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد الفطرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن (كالاحمرار أو الألم)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تصيب حتى ١ من ١٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدبات (بثور) حمراء مرتفعة صغيرة على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (ارتيكاريا)</p><p>&nbsp;</p><p dir="RTL">إذا ازدادت شدة أي من التأثيرات الجانبية، أو لاحظت أي تأثيرات جانبية غير مذكورة في هذه النشرة، فالرجاء إبلاغ طبيبك، مزوّد الرعاية الصحية أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى الأطفال ومتناول أيديهم.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على لصاقة المحقنة وعلى الكرتونة الخارجية بعد &rsquo;EXP&lsquo;.&nbsp;</p><p dir="RTL">احفظه في الثلاجة (٢- ٨ درجة مئوية). لا تجمده.</p><p dir="RTL">احتفظ بالمحاقن مسبقة الملء في الكرتونة الأصلية لحمايتها من الضوء.</p><p dir="RTL">لا تستعمل هذا الدواء إذا كان السائل عكرا أو يحتوي على ندف أو جسيمات كبيرة.</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه&nbsp; الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات سكاي ريزي </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ريسانكيزوماب. تحتوي كل محقنة مسبقة الملء على ٧٥ ملغم من ريسانكيزوماب في ٠٫٨٣ مل من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ديصوديوم سوكسينيت هيكزاهيدريت (ثنائي صوديوم السوكسينيت سداسية الهيدرات)، حمض السوكسينك، سوربيتول، بولي سوربيت ٢٠ وماء للحقن.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو سكاي ريزي ومحتويات العبوة</strong></p><p dir="RTL">سكاي ريزي سائل رائق وعديم اللون إلى مصفرّ في محقنة مسبقة الملء مع واقي للإبرة. قد يحتوي السائل على جزيئات دقيقة بيضاء أو شفافة.</p><p>تحتوي كل عبوة على محقنتين (٢) مسبقتي الملء ومسحتين (٢) كحوليتين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">آبفي دويتشلاند جي إم بي إتش وشركاه كي جي</p><p dir="RTL">نولستراس</p><p dir="RTL">٦٧٠٦١ لودفيغسهافن</p><p dir="RTL">ألمانيا</p><p dir="RTL"><strong>الجهات المصنعة</strong></p><p dir="RTL">بويهرنغر إنغلهايم فارما جي إم بي إتش وشركاه كي جي</p><p dir="RTL">بيبيراخ آن دير ريس، ٨٨٣٩٧، ألمانيا</p><p>المصنع المصدر للتشغيلة :</p><p dir="RTL">آبفي إس آر إل&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">٠٤٠١١ كامبوفيردي دي أبريليا، (لاتينا)، إيطاليا</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة بتاريخ فبراير ٢٠٢٣
	
	للإبلاغ عن التأثيرات الجانبية:

•	المملكة العربية السعودية

المركز الوطني للتيقظ والسلامة الدوائية  
-	فاكس:٧٦٦٢-٢٠٥-١١-٩٦٦+ 
-	مركز الاتصال بهيئة الغذاء والدواء السعودية ١٩٩٩٩
-	البريد الالكتروني: npc.drug@sfda.gov.sa
-	الموقع الالكتروني:  /https://ade.sfda.gov.sa



•	بلدان مجلس التعاون الخليجي الأخرى:

-	الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.



مجلس وزراء الصحة العرب  
 إن هذا دواء 
-	الدواء مستحضر يؤثر على صحّتك، واستهلاكه خلافاً للتعليمات يعرّضك للخطر. 
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك.
-	إن الطبيب والصيدلاني هما الخبيران في الدواء وبنفعه وضرره.  
-	لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك.
-	لا تكرر صرف الدواء بدون استشارة الطبيب.  
-	لا تترك الأدوية في متناول أيدي الأطفال.  

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Skyrizi 75 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 75 mg risankizumab in 0.83 mL solution.

Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody produced in Chinese Hamster Ovary cells using recombinant DNA technology.

Excipients with known effect

This medicinal product contains 68.0 mg sorbitol per 150 mg dose.


For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

The solution is colourless to slightly yellow and clear to slightly opalescent.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Plaque Psoriasis</u></p><p>&nbsp;</p><p>Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Psoriatic Arthritis</u></p><p>&nbsp;</p><p>Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Skyrizi is indicated.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><em>&nbsp;</em></p><p>The recommended dose is 150&nbsp;mg administered as a subcutaneous injection at week 0, week 4, and every 12 weeks thereafter (either as two 75 mg pre-filled syringe injections or one 150 mg pre-filled<br />pen injection)</p><p>&nbsp;</p><p>Consideration should be given to discontinuing treatment in patients who have shown no response after 16&nbsp;weeks of treatment Some plaque psoriasis patients with initial partial response may subsequently improve with continued treatment beyond 16&nbsp;weeks.</p><p>&nbsp;</p><p><u>Missed dose</u></p><p><em>&nbsp;</em></p><p>If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly (aged 65 years and over)</em></p><p>&nbsp;</p><p>No dose adjustment is required (see section 5.2).</p><p>There is limited information in subjects aged &ge;65 years.</p><p>&nbsp;</p><p><em>Renal or hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No specific studies were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of risankizumab . These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The safety and efficacy of risankizumab in children and adolescents aged 5 &nbsp;to 18 years have not been established. No data are available.</p><p>&nbsp;</p><p>There is no relevant use of risankizumab in children aged below 6 years for the indication of moderate to severe plaque psoriasis or in children aged below 5 years for the indication of psoriatic arthritis.</p><p>&nbsp;</p><p><em>Overweight patients</em></p><p>&nbsp;</p><p>No dose adjustment is required (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Skyrizi is administered by subcutaneous injection.</p><p>&nbsp;</p><p>The injections should be administered in the thighs or abdomen, Patients should not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.</p><p>Patients may self-inject Skyrizi after training in subcutaneous injection technique. Patients should be instructed to read the &lsquo;Instructions for use&rsquo; provided in the package leaflet before administration.</p><p>&nbsp;</p><p>Administration of Skyrizi in the upper, outer arm may only be performed by a healthcare professional or caregiver.</p><p>&nbsp;</p><p>Two pre-filled syringes should be injected for the full 150 mg dose. The two injections should be<br />administered at different anatomic locations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important active infections (e.g. active tuberculosis, see section 4.4).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Risankizumab may increase the risk of infection.</p><p>&nbsp;</p><p>In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.</p><p>&nbsp;</p><p>Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Tuberculosis</u></p><p>&nbsp;</p><p>Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed.</p><p><u>&nbsp;</u></p><p><u>Immunisations </u></p><p>&nbsp;</p><p>Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment (see section 5.2).</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>If a serious hypersensivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.</p><p><u>&nbsp;</u></p><p><u>Excipients with known effect</u></p><p>&nbsp;</p><p>This medicinal product contains 68.0&nbsp;mg sorbitol per 150&nbsp;mg dose.</p><p>The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per 150&nbsp;mg dose, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Risankizumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Interactions between risankizumab and inhibitors, inducers, or substrates of medicinal product metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).</p><p>&nbsp;</p><p><u>Concomitant immunosuppressive therapy or phototherapy</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of risankizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure,<strong> </strong>it is preferable to avoid the use of risankizumab during pregnancy.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether risankizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of risankizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Risankizumab has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The most frequently reported adverse reactions were upper respiratory infections (from 13% in<br />psoriasis to 15.6% in Crohn&rsquo;s disease).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions for risankizumab from clinical studies (Table 1) for psoriasis and psoriatic arthritis are listed by MedDRA system organ class and are based on the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1 000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10 000 to &lt;&nbsp;1/1 000); and very rare (&lt;&nbsp;1/10 000).</p><p>&nbsp;</p><p><strong>Table 1:&nbsp; List of adverse reactions </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Upper respiratory infections<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tinea infections<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Folliculitis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache<sup>c</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue<sup>d</sup></p><p>Injection site reactions<sup>e</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp; Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral), tonsillitis, laryngitis, tracheitis</p><p><sup>b</sup> Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, onychomycosis, fungal skin infection</p><p><sup>c</sup>&nbsp; Includes: headache, tension headache, sinus headache</p><p><sup>d</sup>&nbsp; Includes: fatigue, asthenia</p><p><sup>e</sup> Includes: injection site bruising, erythema, haematoma, haemorrhage, irritation, pain, pruritus, reaction, swelling, induration, rash</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Infections</em></p><p>&nbsp;</p><p>The rate of infections was 75.5 events per 100 subject-years from the psoriasis clinical studies and 43.0 events per 100 subject-years from the psoriatic arthritis clinical studies, including long-term exposure to Risankizumab. The majority of cases were non-serious and mild to moderate in severity and did not lead to discontinuation of Risankizumab. The rate of serious infections was 1.7 events per 100 subject-years from the psoriasis studies and 2.6 events per 100 subject-years from the psoriatic arthritis studies (see section 4.4).</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p><u>&nbsp;</u></p><p>Overall, the safety profile observed in patients with psoriatic arthritis treated with risankizumab was consistent with the safety profile observed in patients with plaque psoriasis.</p><p><em>&nbsp;</em></p><p><em>Immunogenicity</em></p><p><em>&nbsp;</em></p><p>As with all therapeutic proteins, there is the potential for immunogenicity with risankizumab. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.</p><p>&nbsp;</p><p>For subjects treated with risankizumab at the recommended clinical dose for up to 52 weeks in psoriasis clinical trials, treatment-emergent anti-drug antibodies and neutralising antibodies were detected in 24% (263/1079) and 14% (150/1079) of evaluated subjects, respectively.</p><p>&nbsp;</p><p>For most subjects with psoriasis, antibodies to risankizumab including neutralising antibodies were not associated with changes in clinical response or safety. Among the few subjects (approximately 1%; 7/1 000 at week 16 and 6/598 at week 52) with high antibody titres (&gt;128), clinical response appeared to be reduced. The incidence of injection site reactions is numerically higher in the anti-drug antibody-positive<u> groups </u>compared with anti-drug antibody-negative groups over short-term (16 weeks: 2.7% vs 1.3%) and longer term treatment (&gt;52 weeks: 5.0% vs 3.3%). The injection site reactions were all mild to moderate in severity, none were serious, and none led to discontinuation of risankizumab.</p><p>&nbsp;</p><p>For subjects treated with risankizumab at the recommended clinical dose for up to 28 weeks in psoriatic arthritis clinical trials, treatment-emergent anti-drug antibodies and neutralizing antibodies were detected in 12.1% (79/652) and 0% (0/652) of evaluated subjects, respectively. Antibodies to risankizumab were not associated with changes in clinical response or safety for psoriatic arthritis.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>There is limited safety information in subjects aged &ge;65 years.</p><p><em>&nbsp;</em></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><v:rect
 id="Rectangle_x0020_1441242383" o:spid="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:-3.3pt;margin-top:12.7pt;width:460.8pt;
 height:23.25pt;z-index:251662336;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC18</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p><em>&nbsp;</em></p><p>Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.</p><p><u>&nbsp;</u></p><p>In a study of subjects with psoriatic arthritis, statistically significant and clinically meaningful reduction from baseline was observed at week 24 in IL-23 and IL-17-associated biomarkers, including serum IL-17A, IL-17F, and IL-22 following treatment with risankizumab 150&nbsp;mg subcutaneously at week 0, week 4, and every 12 weeks thereafter.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Plaque Psoriasis</u></em></p><p><em>&nbsp;</em></p><p>The efficacy and safety of risankizumab was assessed in 2109 subjects with moderate to severe plaque psoriasis in four multicentre, randomised, double-blind studies (ULTIMMA-1, ULTIMMA-2, IMMHANCE, and IMMVENT). Enrolled subjects were 18 years of age and older with plaque psoriasis who had a body surface area (BSA) involvement of &ge;10%, a static Physician Global Assessment (sPGA) score of &ge;3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0&nbsp;to 4, a Psoriasis Area and Severity Index (PASI) score &ge;12, and who were candidates for systemic therapy or phototherapy.</p><p>&nbsp;</p><p>Overall, subjects had a median baseline PASI score of 17.8, a median BSA of 20.0%, and a median baseline DLQI score of 13.0. Baseline sPGA score was severe in 19.3% of subjects and moderate in 80.7% of subjects. A total of 9.8% of study subjects had a history of diagnosed psoriatic arthritis.</p><p>&nbsp;</p><p>Across all studies, 30.9% of subjects were na&iuml;ve to any systemic therapy (including non-biologic and biologic), 38.1% had received prior phototherapy or photochemotherapy, 48.3% had received prior non<!--[if gte msEquation 12]><m:oMath><span
 lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif;
 mso-ansi-language:EN-GB'>‑</span></m:oMath><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.6pt;
 height:12.6pt'>
 <v:imagedata src="file:///C:/Users/almohax/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" chromakey="white"/>
</v:shape><![endif]--><img width="5" height="17" src="file:///C:/Users/almohax/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" />biologic systemic therapy, 42.1% had received prior biologic therapy, and 23.7% had received at least one anti‑TNF alpha agent for the treatment of psoriasis.</p><p>&nbsp;</p><p><u>ULTIMMA-1 and ULTIMMA-2</u></p><p>&nbsp;</p><p>ULTIMMA-1 and ULTIMMA-2 enrolled 997 subjects (598 randomised to risankizumab 150&nbsp;mg, 199 to ustekinumab 45&nbsp;mg or 90&nbsp;mg [according to baseline weight], and 200 to placebo). Subjects received treatment at week 0, week 4, and every 12 weeks thereafter. The two co-primary endpoints in ULTIMMA-1 and ULTIMMA-2 were the proportion of subjects who achieved 1) PASI 90 response and 2) sPGA score of clear or almost clear (sPGA 0 or 1) at week 16 versus placebo. The results for the co-primary and other endpoints are presented in Table 2 and Figure 1.</p><p>&nbsp;</p><p><strong>Table 2:&nbsp; Efficacy and quality of life results in adults with plaque psoriasis in ULTIMMA‑1 and ULTIMMA‑2</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:649px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>ULTIMMA‑1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>ULTIMMA‑2</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Risankizumab </strong><br /><strong>(N=304)</strong><br /><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Ustekinumab<br />(N=100)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><br /><strong>(N=102)</strong><br /><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Risankizumab </strong><br /><strong>(N=294)</strong><br /><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Ustekinumab<br />(N=99)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><br /><strong>(N=98)</strong><br /><strong>n (%)</strong></p></td></tr><tr><td colspan="7"><p><strong>sPGA of clear or almost clear (0 or 1)</strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16<sup>a</sup></strong></p></td><td><p>267 (87.8)</p></td><td><p>63 (63.0)</p></td><td><p>8 (7.8)</p></td><td><p>246 (83.7)</p></td><td><p>61 (61.6)</p></td><td><p>5 (5.1)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>262 (86.2)</p></td><td><p>54 (54.0)</p></td><td><p>--</p></td><td><p>245 (83.3)</p></td><td><p>54 (54.5)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p><strong>sPGA of clear (0)</strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16</strong></p></td><td><p>112 (36.8)</p></td><td><p>14 (14.0)</p></td><td><p>2 (2.0)</p></td><td><p>150 (51.0)</p></td><td><p>25 (25.3)</p></td><td><p>3 (3.1)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>175 (57.6)</p></td><td><p>21 (21.0)</p></td><td><p>--</p></td><td><p>175 (59.5)</p></td><td><p>30 (30.3)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p><strong>PASI 75</strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 12</strong></p></td><td><p>264 (86.8)</p></td><td><p>70 (70.0)</p></td><td><p>10 (9.8)</p></td><td><p>261 (88.8)</p></td><td><p>69 (69.7)</p></td><td><p>8 (8.2)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>279 (91.8)</p></td><td><p>70 (70.0)</p></td><td><p>--</p></td><td><p>269 (91.5)</p></td><td><p>76 (76.8)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p><strong>PASI 90</strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16<sup>a </sup></strong></p></td><td><p>229 (75.3)</p></td><td><p>42 (42.0)</p></td><td><p>5 (4.9)</p></td><td><p>220 (74.8)</p></td><td><p>47 (47.5)</p></td><td><p>2 (2.0)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>249 (81.9)</p></td><td><p>44 (44.0)</p></td><td><p>--</p></td><td><p>237 (80.6)</p></td><td><p>50 (50.5)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p><strong>PASI 100</strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16</strong></p></td><td><p>109 (35.9)</p></td><td><p>12 (12.0)</p></td><td><p>0 (0.0)</p></td><td><p>149 (50.7)</p></td><td><p>24 (24.2)</p></td><td><p>2 (2.0)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>171 (56.3)</p></td><td><p>21 (21.0)</p></td><td><p>--</p></td><td><p>175 (59.5)</p></td><td><p>30 (30.3)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p><strong>DLQI 0 or 1<sup>b</sup></strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16</strong></p></td><td style="vertical-align:top"><p>200 (65.8)</p></td><td style="vertical-align:top"><p>43 (43.0)</p></td><td style="vertical-align:top"><p>8 (7.8)</p></td><td style="vertical-align:top"><p>196 (66.7)</p></td><td style="vertical-align:top"><p>46 (46.5)</p></td><td style="vertical-align:top"><p>4 (4.1)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td style="vertical-align:top"><p>229 (75.3)</p></td><td style="vertical-align:top"><p>47 (47.0)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>208 (70.7)</p></td><td style="vertical-align:top"><p>44 (44.4)</p></td><td style="vertical-align:top"><p>&nbsp;--</p></td></tr><tr><td colspan="7"><p><strong>PSS 0 (symptom-free)<sup>c</sup></strong></p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 16</strong></p></td><td><p>89 (29.3)</p></td><td><p>15 (15.0)</p></td><td><p>2 (2.0)</p></td><td><p>92 (31.3)</p></td><td><p>15 (15.2)</p></td><td><p>0 (0.0)</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; Week 52</strong></p></td><td><p>173 (56.9)</p></td><td><p>30 (30.0)</p></td><td><p>--</p></td><td><p>160 (54.4)</p></td><td><p>30 (30.3)</p></td><td><p>--</p></td></tr><tr><td colspan="7"><p>All comparisons of risankizumab versus ustekinumab and placebo achieved p&lt;0.001 except for PASI 75 at week 52 in ULTIMMA-2 where p=0.001</p><p><sup>a&nbsp; </sup>Co-primary endpoints versus placebo</p><p><sup>b</sup> No impact on health-related quality of life</p><p><sup>c</sup> Psoriasis Symptom Scale (PSS) of 0 means no symptoms of pain, itching, redness, and burning during the last 24 hours</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 1:&nbsp; Time course of mean percent change from baseline of PASI in ULTIMMA-1 and</strong></p><p><img alt="" width="522" height="361" src="data:image/png;base64,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" /></p><p>RZB = risankizumab</p><p>UST = ustekinumab</p><p>PBO = placebo</p><p>p&lt;0.001 at each time point</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Examination of age, gender, race, body weight &le;130 kg, baseline PASI score, concurrent psoriatic arthritis, previous non-biologic systemic treatment, previous biologic treatment, and previous failure of a biologic did not identify differences in response to risankizumab among these subgroups.</p><p>&nbsp;</p><p>Improvements were observed in psoriasis involving the scalp, the nails, and the palms and soles at week 16 and week 52 in subjects treated with risankizumab.</p><p>&nbsp;</p><p><strong>Table 3:&nbsp; </strong><strong>Mean changes from baseline in NAPSI, PPASI, and PSSI</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ULTIMMA-1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ULTIMMA-2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IMMHANCE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Risankizumab</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Risankizumab</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Risankizumab</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>NAPSI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>16 (SE)</strong></p></td><td><p>N=178;</p><p>-9.0 (1.17)</p></td><td><p>N=56;</p><p>2.1 (1.86)</p><p>***</p></td><td><p>N=177;</p><p>-7.5 (1.03)</p></td><td><p>N=49;</p><p>3.0 (1.76)</p><p>***</p></td><td><p>N=235;</p><p>-7.5 (0.89)</p></td><td><p>N=58;</p><p>2.5</p><p>(1.70)</p><p>***</p></td></tr><tr><td style="vertical-align:top"><p><strong>PPASI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>16 (SE)</strong></p></td><td><p>N=95;</p><p>-5.93 (0.324)</p><p>&nbsp;</p></td><td><p>N=34;</p><p>-3.17</p><p>(0.445)</p><p>***</p></td><td><p>N=86;</p><p>-7.24 (0.558)</p></td><td><p>N=23;</p><p>-3.74</p><p>(1.025)</p><p>**</p></td><td><p>N=113;</p><p>-7.39 (0.654)</p><p>&nbsp;</p></td><td><p>N=26;</p><p>-0.27</p><p>(1.339)</p><p>***</p></td></tr><tr><td style="vertical-align:top"><p><strong>PSSI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>16 (SE)</strong></p></td><td><p>N=267;</p><p>-17.6 (0.47)</p></td><td><p>N=92;</p><p>-2.9</p><p>(0.69)</p><p>***</p></td><td><p>N=252;</p><p>-18.4 (0.52)</p></td><td><p>N=83;</p><p>-4.6</p><p>(0.82)</p><p>***</p></td><td><p>N=357;</p><p>-20.1 (0.40)</p></td><td><p>N=88;</p><p>-5.5</p><p>(0.77)</p><p>***</p></td></tr><tr><td style="vertical-align:top"><p><strong>NAPSI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>52 (SE)</strong></p></td><td><p>N=178;</p><p>-15.7 (0.94)</p></td><td><p>-</p></td><td><p>N=183;</p><p>-16.7 (0.85)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>PPASI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>52 (SE)</strong></p></td><td><p>N=95;</p><p>-6.16 (0.296)</p><p>&nbsp;</p></td><td><p>-</p></td><td><p>N=89;</p><p>-8.35 (0.274)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>PSSI:</strong></p><p><strong>Change</strong></p><p><strong>at Week</strong></p><p><strong>52 (SE)</strong></p></td><td><p>N=269;</p><p>-17.9 (0.34)</p></td><td><p>-</p></td><td><p>N=259;</p><p>-18.8 (0.24)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Nail Psoriasis Severity Index (NAPSI), Palmoplantar Psoriasis Severity Index (PPASI), Psoriasis Scalp Severity Index (PSSI), and Standard Error (SE)</p><p>** P &lt; 0.01 comparing to risankizumab</p><p>*** P &lt; 0.001 comparing to risankizumab</p></td></tr></tbody></table><p>&nbsp;</p><p>Anxiety and depression, as measured by the Hospital Anxiety and Depression Scale (HADS), improved in the risankizumab group at week 16 compared with the placebo group.</p><p>&nbsp;</p><p><em><u>Maintenance of response</u></em></p><p>&nbsp;</p><p>In an integrated analysis of subjects receiving risankizumab in ULTIMMA-1 and ULTIMMA-2 for PASI 100 responders at week 16, 79.8% (206/258) of the subjects who continued on risankizumab maintained the response at week 52. For PASI 90 responders at week 16, 88.4% (398/450) of subjects maintained the response at week 52.</p><p>&nbsp;</p><p>The safety profile of risankizumab with up to 77 weeks of exposure was consistent with the profile observed up to 16 weeks.</p><p>&nbsp;</p><p><u>IMMHANCE </u></p><p><u>&nbsp;</u></p><p>IMMHANCE enrolled 507 subjects (407 randomised to risankizumab 150&nbsp;mg and 100 to placebo). Subjects received treatment at week 0, week 4, and every 12 weeks thereafter. Subjects who were originally on risankizumab and had a sPGA response of clear or almost clear at week 28 were re-randomised to continue risankizumab every 12 weeks through week 88 (with follow-up 16 weeks after last risankizumab dose) or have treatment withdrawn.</p><p>&nbsp;</p><p>At week 16, risankizumab was superior to placebo on the co-primary endpoints of sPGA of clear or almost clear (83.5% risankizumab vs 7.0% placebo) and PASI 90 (73.2% risankizumab vs 2.0% placebo).</p><p>&nbsp;</p><p>Of the 31 subjects from the IMMHANCE study with latent tuberculosis (TB) who did not receive prophylaxis during the study, none developed active TB during the mean follow-up of 55 weeks on risankizumab.</p><p>&nbsp;</p><p>Among subjects with sPGA of clear or almost clear at week 28 in IMMHANCE, 81.1% (90/111) of subjects re-randomised to continued treatment with risankizumab maintained this response at week 104 compared with<u> </u>7.1% (16/225) who were re-randomised to withdrawal from risankizumab. Of these subjects, 63.1% (70/111) of subjects re-randomised to continued treatment with risankizumab achieved a sPGA clear response at week 104 compared with 2.2% (5/225) who were re-randomised to withdrawal from risankizumab.</p><p>&nbsp;</p><p>Among subjects who achieved sPGA of clear or almost clear at week 28 and relapsed to sPGA of moderate or severe following withdrawal from risankizumab, 83.7% (128/153) regained sPGA of clear or almost clear after 16 weeks of retreatment. Loss of sPGA of clear or almost clear was observed as early as 12 weeks after a missed dose. Of those subjects who were re-randomised to withdraw from treatment, 80.9% (182/225) relapsed and the median time to relapse was 295 days. No characteristics were identified to predict the time to loss of response or likelihood of regaining response at the individual patient level.</p><p><u>&nbsp;</u></p><p><u>IMMVENT</u></p><p><em>&nbsp;</em></p><p>IMMVENT enrolled 605 subjects (301 randomised to risankizumab and 304 to adalimumab). Subjects randomised to risankizumab received 150&nbsp;mg of treatment at week 0, week 4, and every 12 weeks thereafter. Subjects randomised to adalimumab received 80&nbsp;mg at week 0, 40&nbsp;mg at week 1 and 40&nbsp;mg every other week through week 15. Starting at week 16, subjects who were receiving adalimumab continued or switched treatment based on response:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;PASI 50 were switched to risankizumab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PASI 50 to &lt;PASI 90 were re-randomised to either continue adalimumab or switch to risankizumab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PASI 90 continued to receive adalimumab</p><p>&nbsp;</p><p>Results are presented in Table 4.</p><p>&nbsp;</p><p><strong>Table 4:&nbsp; Efficacy and quality of life results at week 16 in adults with plaque psoriasis in IMMVENT</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:468px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Risankizumab</strong><br /><strong>(N=301)</strong><br /><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>(N=304)</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td><p><strong>sPGA of clear or almost clear<sup>a</sup></strong></p></td><td><p>252 (83.7)</p></td><td><p>183 (60.2)</p></td></tr><tr><td><p><strong>PASI 75</strong></p></td><td><p>273 (90.7)</p></td><td><p>218 (71.7)</p></td></tr><tr><td><p><strong>PASI 90<sup>a</sup></strong></p></td><td><p>218 (72.4)</p></td><td><p>144 (47.4)</p></td></tr><tr><td><p><strong>PASI 100</strong></p></td><td><p>120 (39.9)</p></td><td><p>70 (23.0)</p></td></tr><tr><td><p><strong>DLQI 0 or 1<sup>b</sup></strong></p></td><td><p>198 (65.8)</p></td><td><p>148 (48.7)</p></td></tr><tr><td colspan="3"><p>All comparisons achieved p&lt;0.001<sup> </sup></p><p><sup>a </sup>Co-primary endpoints</p><p><sup>b</sup> No impact on health-related quality of life</p></td></tr></tbody></table><p>&nbsp;</p><p>For subjects who had PASI 50 to &lt;PASI 90 with adalimumab at week 16 and were re-randomised, differences in PASI 90 response rates between switching to risankizumab and continuing adalimumab were noted 4 weeks after re-randomisation (49.1% vs 26.8%, respectively).</p><p>&nbsp;</p><p>Results 28 weeks after re-randomisation are presented in Table 5 and Figure 2.</p><p>&nbsp;</p><p><strong>Table 5:&nbsp; Efficacy results 28 weeks after re-randomisation in IMMVENT</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:468px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Switched to Risankizumab</strong><br /><strong>(N=53)</strong><br /><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Continued on Adalimumab</strong></p><p><strong>(N=56)</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td><p><strong>PASI 90</strong></p></td><td><p>35 (66.0)</p></td><td><p>12 (21.4)</p></td></tr><tr><td><p><strong>PASI 100</strong></p></td><td><p>21 (39.6)</p></td><td><p>4 (7.1)</p></td></tr><tr><td colspan="3"><p>All comparisons achieved p&lt;0.001<sup> </sup></p></td></tr></tbody></table><p>&nbsp;</p><p><img alt="" width="524" height="295" src="data:image/png;base64,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" /></p><p>ADA/ADA:&nbsp;Subjects randomised to adalimumab and continued on adalimumab</p><p>ADA/RZB:&nbsp;Subjects randomised to adalimumab and switched to risankizumab</p><p>p&lt;0.05 at week 4, and p&lt;0.001 at each time point beginning at week 8</p><p><u>&nbsp;</u></p><p>In 270 subjects who switched from adalimumab to risankizumab without a washout period, the safety profile of risankizumab was similar to that in subjects who initiated risankizumab after wash out of any prior systemic therapies.</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis</u></em></p><p>&nbsp;</p><p>Risankizumab has been shown to improve signs and symptoms, physical function, health-related quality of life, and the proportion of subjects with no radiographic progression in adults with active psoriatic arthritis (PsA).</p><p>&nbsp;</p><p>The safety and efficacy of risankizumab were assessed in 1&nbsp;407 subjects with active PsA in 2 randomised, double-blind, placebo-controlled studies (964 in KEEPSAKE1 and 443 in KEEPSAKE2).</p><p>&nbsp;</p><p>Subjects in these studies had a diagnosis of PsA for at least 6 months based on the Classification Criteria for Psoriatic Arthritis (CASPAR), a median duration of PsA of 4.9 years at baseline, &ge;&nbsp;5 tender joints and &ge;&nbsp;5 swollen joints, and active plaque psoriasis or nail psoriasis at baseline. 55.9% of subjects had &ge;&nbsp;3% BSA with active plaque psoriasis. 63.4% and 27.9% of subjects had enthesitis and dactylitis, respectively. In KEEPSAKE1, where nail psoriasis was further assessed, 67.3% had nail psoriasis.</p><p>&nbsp;</p><p>In both studies, subjects were randomised to receive risankizumab 150&nbsp;mg or placebo at weeks 0, 4, and 16. Starting from week 28, all subjects received risankizumab every 12 weeks.</p><p>&nbsp;</p><p>In KEEPSAKE1, all subjects had a previous inadequate response or intolerance to non-biologic DMARD therapy and were biologic na&iuml;ve. In KEEPSAKE2, 53.5% of subjects had a previous inadequate response or intolerance to non-biologic DMARD therapy and 46.5% of subjects had a previous inadequate response or intolerance to biologic therapy.</p><p>&nbsp;</p><p>In both studies, 59.6% of subjects were receiving concomitant methotrexate (MTX), 11.6% were receiving concomitant non-biologic DMARDs other than MTX, and 28.9% were receiving risankizumab monotherapy.</p><p><u>&nbsp;</u></p><p><u>Clinical Response</u></p><p>&nbsp;</p><p>Treatment with risankizumab resulted in significant improvement in measures of disease activity compared with placebo at week 24. For both studies, the primary endpoint was the proportion of subjects who achieved an American College of Rheumatology (ACR) 20 response at week 24. The key efficacy results are shown in Table 6.</p><p>&nbsp;</p><p><strong>Table 6. Efficacy results in studies KEEPSAKE1 and KEEPSAKE2 </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td colspan="2"><p><strong><u>KEEPSAKE1</u></strong></p></td><td colspan="2"><p><strong><u>KEEPSAKE2</u></strong></p></td></tr><tr><td><p><strong><u>Endpoint</u></strong></p></td><td><p><strong><u>Placebo</u></strong></p><p><strong><u>N=481</u></strong></p><p><u>n (%)</u></p></td><td><p><strong><u>Risankizumab </u></strong></p><p><strong><u>N=483</u></strong></p><p><u>n (%)</u></p></td><td><p><strong><u>Placebo</u></strong></p><p><strong><u>N=219</u></strong></p><p><u>n (%)</u></p></td><td><p><strong><u>Risankizumab </u></strong></p><p><strong><u>N=224</u></strong></p><p><u>n (%)</u></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><u>ACR20 Response </u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 16</p></td><td><p>161 (33.4)</p></td><td><p>272 (56.3)<strong><sup> a</sup></strong></p></td><td><p>55 (25.3)<strong><sup> </sup></strong></p></td><td><p>108 (48.3)<strong><sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 24</p></td><td><p>161 (33.5)</p></td><td><p>277 (57.3)<strong><sup> a</sup></strong></p></td><td><p>58 (26.5)<strong><sup> </sup></strong></p></td><td><p>115 (51.3)<strong><sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 52*</p></td><td><p>-</p></td><td><p>338/433 (78.1)</p></td><td><p>-</p></td><td><p>131/191 (68.6)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><u>ACR50 Response </u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 24</p></td><td><p>54 (11.3)</p></td><td><p>162 (33.4)<strong><sup> b</sup></strong></p></td><td><p>20 (9.3)</p></td><td><p>59 (26.3)<strong><sup> b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 52*</p></td><td><p>-</p></td><td><p>209/435 (48.0)</p></td><td><p>-</p></td><td><p>72/192 (37.5)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><u>ACR70 Response </u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 24</p></td><td><p>23 (4.7)</p></td><td><p>74 (15.3)<strong><sup> b</sup></strong></p></td><td><p>13 (5.9)</p></td><td><p>27 (12.0)<strong><sup> c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 52*</p></td><td><p>-</p></td><td><p>125/437 (28.6)</p></td><td><p>-</p></td><td><p>37/192 (19.3)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Resolution of Enthesitis (LEI=0) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 24*</p></td><td><p>156/448 (34.8) <strong><sup>d</sup></strong></p></td><td><p>215/444 (48.4)<strong><sup> a, d</sup></strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 52*</p></td><td><p>-</p></td><td><p>244/393 (62.1)<strong><sup> d</sup></strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><u>Resolution of Dactylitis (LDI=0)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 24*</p></td><td><p>104/204 (51.0) <strong><sup>e</sup></strong></p></td><td><p>128/188 (68.1)<strong><sup> a, e</sup></strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Week 52*</p></td><td><p>-</p></td><td><p>143/171 (83.6)<strong><sup> e</sup></strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><u>Minimal Disease Activity (MDA) Response </u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Week 24</p></td><td style="vertical-align:top"><p>49 (10.2)</p></td><td style="vertical-align:top"><p>121 (25.0)<strong><sup> a</sup></strong></p></td><td style="vertical-align:top"><p>25 (11.4)</p></td><td style="vertical-align:top"><p>57 (25.6)<strong><sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Week 52*</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>183/444 (41.2)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>61/197 (31.0)</p></td></tr><tr><td colspan="5"><p>*data are shown for available subjects in the format of n/N observed (%)</p><p><sup>a.&nbsp;&nbsp;&nbsp; </sup>multiplicity-controlled p&le;0.001 risankizumab vs placebo comparison.</p><p><sup>b.&nbsp;&nbsp;&nbsp; </sup>nominal p&le;0.001 risankizumab vs placebo comparison.</p><p><sup>c.&nbsp;&nbsp;&nbsp; </sup>nominal p&le;0.05 risankizumab vs placebo comparison.</p><p><sup>d.&nbsp;&nbsp;&nbsp; </sup>Summarized from pooled data from KEEPSAKE1 and KEEPSAKE2 for subjects with baseline LEI &gt;0.</p><p><sup>e.&nbsp;&nbsp;&nbsp; </sup>Summarized from pooled data from KEEPSAKE1 and KEEPSAKE2 for subjects with baseline LDI &gt;0.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Response over time</u></em></p><p><em><u>&nbsp;</u></em></p><p>In KEEPSAKE1, a greater ACR20 response was observed in the risankizumab group compared to placebo as early as week 4 (25.7%) and the treatment difference continued over time to week 24 (Figure 3).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure 3. Percent of subjects achieving ACR20 responses in study KEEPSAKE1 through week 24</strong></p><p>&nbsp;</p><p><img alt="" width="522" height="348" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p>A greater ACR20 response for risankizumab versus placebo was seen as early as week 4 in 19.6% of subjects in KEEPSAKE2.</p><p>&nbsp;</p><p>Responses observed in risankizumab groups were similar regardless of concomitant non-biologic DMARD use, number of prior non‑biologic DMARDs, age, gender, race, and BMI. In KEEPSAKE2, responses were seen regardless of prior biologic therapy.</p><p>&nbsp;</p><p>The safety profile of risankizumab with up to 52 weeks of exposure was consistent with the profile observed up to 24 weeks.</p><p>&nbsp;</p><p>In both studies, the proportion of subjects achieving modified PsA Response Criteria&nbsp;(PsARC) at week 24 was higher in subjects receiving risankizumab compared with placebo. In addition, subjects receiving risankizumab achieved greater improvement in Disease Activity Score (28 joints) using CRP (DAS28-CRP) compared with placebo at week 24. Improvements were maintained through week 52 for PsARC and DAS28-CRP.</p><p>&nbsp;</p><p>Treatment with risankizumab resulted in improvements in individual ACR components, Health Assessment Questionnaire-Disability Index (HAQ-DI), pain assessment, and high-sensitivity C-reactive protein&nbsp;(hsCRP) compared with placebo.</p><p>&nbsp;</p><p>Treatment with risankizumab resulted in statistically significant improvement in the skin manifestations of psoriasis in subjects with PsA.</p><p>&nbsp;</p><p>Treatment with risankizumab resulted in statistically significant improvement in the modified Nail Psoriasis Severity Index&nbsp;(mNAPSI) and the 5-point Physician&rsquo;s Global Assessment of Fingernail Psoriasis&nbsp;(PGA-F) scores in subjects with nail psoriasis at baseline (67.3%) in KEEPSAKE1. This improvement was maintained through week 52 (see Table 7).</p><p>&nbsp;</p><p><strong>Table 7. Nail psoriasis efficacy results in KEEPSAKE1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:579px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N=338</strong></p></td><td><p><strong>Risankizumab</strong></p><p><strong>N=309</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>mNAPSI change from baseline<sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24<strong><sup> </sup></strong></p></td><td style="vertical-align:top"><p>-5.57</p></td><td style="vertical-align:top"><p>-9.76<strong><sup> b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-13.64</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PGA-F change from baseline<sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.8 <strong><sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-1.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PGA-F clear/minimal and &ge;2-grade improvement<sup> c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 24 n (%)</p></td><td style="vertical-align:top"><p>30 (15.9)</p></td><td style="vertical-align:top"><p>71<strong><sup> </sup></strong></p><p>(37.8)<strong><sup> d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 52 n (%)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>105 (58.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a.&nbsp;&nbsp;&nbsp; </sup>Summarized for subjects with baseline nail psoriasis (Placebo N=338; risankizumab N=309; at week 52, for mNAPSI, observed risankizumab N=290, for PGA-F, observed risankizumab N=291).</p><p><sup>b.&nbsp;&nbsp; </sup>Multiplicity-controlled p&le;0.001 risankizumab vs placebo comparison.</p><p><sup>c.&nbsp;&nbsp;&nbsp; </sup>Summarized for subjects with nail psoriasis and a PGA-F overall global assessment score of &lsquo;Mild&rsquo;, &lsquo;Moderate&rsquo; or &lsquo;Severe&rsquo; at Baseline (Placebo N=190; risankizumab N=188, at week 52 observed risankizumab N=181).</p><p><sup>d.&nbsp;&nbsp; </sup>Nominal p&le;0.001 risankizumab vs placebo comparison.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Radiographic Response</u></p><p>&nbsp;</p><p>In KEEPSAKE1, inhibition of progression of structural damage was assessed radiographically and expressed as the change in modified Total Sharp Score&nbsp;(mTSS) at week 24, compared with baseline. The mTSS score was modified for PsA by addition of hand distal interphalangeal&nbsp;(DIP) joints. At week 24, the mean progression of structural damage with risankizumab (mean mTSS 0.23) compared with placebo (mean mTSS 0.32) was not statistically significant. At week 24, the proportion of subjects with no radiographic progression (defined as a change from baseline in mTSS&nbsp;&le;&nbsp;0) was higher with risankizumab (92.4%) compared with placebo (87.7%). This response was maintained through week 52.</p><p>&nbsp;</p><p><u>Physical Function and Health Related Quality of Life</u></p><p>&nbsp;</p><p>In both studies, subjects treated with risankizumab showed statistically significant improvement from baseline in physical function as assessed by HAQ-DI at week 24&nbsp;(KEEPSAKE1 (-0.31) compared with placebo&nbsp;(-0.11)&nbsp;(p&nbsp;&le;0.001)), (KEEPSAKE2 (-0.22) compared with placebo (-0.05) (p&nbsp;&le;0.001)).&nbsp; At week 24, a greater proportion of subjects achieved a clinically meaningful reduction of at least 0.35 in HAQ-DI score from baseline in the risankizumab group compared with placebo. Improvements in physical function were maintained through week 52.</p><p>&nbsp;</p><p>In both studies, subjects treated with risankizumab demonstrated significant improvements in the SF‑36 V2 physical component summary scores and in FACIT‑Fatigue scores at week 24, compared with placebo, with improvements maintained through week 52.</p><p><u>&nbsp;</u></p><p>At baseline, psoriatic spondylitis was reported in 19.6% (7.9% diagnosed by radiograph or MRI) of subjects in KEEPSAKE1 and 19.6% (5% diagnosed by radiograph or MRI) of subjects in KEEPSAKE2. Subjects with clinically assessed psoriatic spondylitis who were treated with risankizumab showed improvements from baseline in Bath Ankylosing Spondylitis Disease Activity Index&nbsp;(BASDAI) scores compared with placebo at week 24. Improvements were maintained through week 52.<strong> </strong>There is insufficient evidence of the efficacy of risankizumab in subjects with radiograph- or MRI-confirmed ankylosing spondylitis-like psoriatic arthropathy due to the small number of subjects studied.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with risankizumab in one or more subsets of the paediatric population in the treatment of plaque psoriasis <u>and psoriatic arthritis</u> (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of risankizumab was similar between subjects with plaque psoriasis and subjects with psoriatic arthritis.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Risankizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure across dose ranges of 18 to 300&nbsp;mg and 0.25 to 1&nbsp;mg/kg administered subcutaneously, and 200 to 1200&nbsp;mg and 0.01 to 5&nbsp;mg/kg administered intravenously.</p><p>&nbsp;</p><p>Following subcutaneous dosing of risankizumab, peak plasma concentrations were achieved between 3‑14 days after dosing with an estimated absolute bioavailability of 89%. With dosing of 150&nbsp;mg at week 0, week 4, and every 12 weeks thereafter, estimated steady-state peak and trough plasma concentrations are 12 and 2&nbsp;&micro;g/mL, respectively.</p><p>Bioequivalence was demonstrated between a single risankizumab 150 mg injection and two<br />risankizumab 75 mg injections in pre-filled syringe.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean (&plusmn;standard deviation) steady-state volume of distribution (V<sub>ss</sub>) of risankizumab was 11.4 (&plusmn;2.7) L in Phase 3 studies in subjects with psoriasis, indicating that the distribution of risankizumab is primarily confined to the vascular and interstitial spaces.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Therapeutic IgG monoclonal antibodies are typically degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs. Risankizumab is not expected to be metabolised by cytochrome P450 enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The mean (&plusmn;standard deviation) systemic clearance (CL) of risankizumab was 0.3 (&plusmn;0.1) L/day in Phase 3 studies in subjects with psoriasis. The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in subjects with psoriasis.</p><p>&nbsp;</p><p>As an IgG1 monoclonal antibody, risankizumab is not expected to be filtered by glomerular filtration in the kidneys or to be excreted as an intact molecule in the urine.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p><u>&nbsp;</u></p><p>Risankizumab exhibited linear pharmacokinetics with approximately dose-proportional increases in systemic exposure (C<sub>max</sub> and AUC) in the evaluated dose ranges of 18 to 300&nbsp;mg or 0.25 to 1 mg/kg subcutaneous administration in healthy subjects or subjects with psoriasis.</p><p>&nbsp;</p><p><u>Interactions</u></p><p>&nbsp;</p><p>An interaction study was conducted in subjects with plaque psoriasis to assess the effect of repeated administration of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) sensitive probe substrates. The exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate) and midazolam (CYP3A substrate) following risankizumab treatment were comparable to their exposures prior to risankizumab treatment, indicating no clinically meaningful interactions through these enzymes.</p><p>&nbsp;</p><p>Population pharmacokinetic analyses indicated that risankizumab exposure was not impacted by concomitant treatment used by some subjects with plaque psoriasis or psoriatic arthritis during the clinical studies.</p><p>&nbsp;</p><p><u>Special populations </u></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of risankizumab in paediatric subjects has not been established.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>&nbsp;</p><p>Of the 2234 subjects with plaque psoriasis exposed to risankizumab, 243 were 65 years or older and 24 subjects were 75 years or older. Of the 1&nbsp;542 subjects with psoriatic arthritis exposed to risankizumab<u>, </u>246 were 65 years or older and 34 subjects were 75 years or older. No overall differences in risankizumab exposure were observed between older and younger subjects who received risankizumab.</p><p>&nbsp;</p><p><em><u>Patients with renal or hepatic impairment</u></em></p><p>&nbsp;</p><p>No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab. Based on population pharmacokinetic analyses, serum creatinine levels, creatinine clearance, or hepatic function markers (ALT/AST/bilirubin) did not have a meaningful impact on risankizumab clearance in subjects with plaque psoriasis or psoriatic arthritis.</p><p>&nbsp;</p><p>As an IgG1 monoclonal antibody, risankizumab is mainly eliminated via intracellular catabolism and is not expected to undergo metabolism via hepatic cytochrome P450 enzymes or renal elimination.</p><p>&nbsp;</p><p><em><u>Body weight</u></em></p><p>&nbsp;</p><p>Risankizumab clearance and volume of distribution increase as body weight increases which may result in reduced efficacy in subjects with high body weight (&gt;130&nbsp;kg). However, this observation is based on a limited number of subjects. No dose adjustment based on body weight is currently recommended.</p><p>&nbsp;</p><p><em><u>Gender or race</u></em></p><p>&nbsp;</p><p>The clearance of risankizumab was not significantly influenced by gender or race in adult subjects with plaque psoriasis or psoriatic arthritis. No clinically meaningful differences in risankizumab exposure were observed in Chinese or Japanese subjects compared with Caucasian subjects in a clinical pharmacokinetic study.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data revealed no special hazard for humans based on repeat-dose toxicity studies including safety pharmacology evaluations, and a reproductive and developmental toxicity study in cynomolgus monkeys at doses of up to 50&nbsp;mg/kg/week (producing exposures of about 70 times the clinical exposure at maximum recommended human dose [MRHD]).</p><p>&nbsp;</p><p>Mutagenicity and carcinogenicity studies have not been conducted with risankizumab. In a 26-week chronic toxicology study in cynomolgus monkeys at doses of up to 50&nbsp;mg/kg/week (about 70 times the clinical exposure at the MRHD), there were no pre-neoplastic or neoplastic lesions observed and no adverse immunotoxicity or cardiovascular effects were noted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium succinate hexahydrate : 0.88 mg</p><p>Succinic acid : 0.049 mg</p><p>Sorbitol : 34 mg</p><p>Polysorbate 20 : 0.17 mg</p><p>Water for injections : QS</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-filled glass syringe with a fixed needle and needle cover, assembled in an automatic needle guard.</p><p>&nbsp;</p><p>Skyrizi is available in packs containing 2 pre-filled syringes and 2 alcohol pads.</p><p>&nbsp;</p><p>Not all presentations may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before injecting, patients may remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight (15 to 30 minutes) without removing the pre-filled syringes from the carton.</p><p>&nbsp;</p><p>The solution should be colourless to slightly yellow and clear to slightly opalescent.</p><p>&nbsp;</p><p>Two pre-filled syringes should be injected for the full 150&nbsp;mg dose.</p><p>&nbsp;</p><p>Prior to use, a visual inspection of each pre-filled syringe is recommended. The<br />solution may contain a few translucent to white product-related particles. Skyrizi should not be used if<br />the solution is cloudy or discoloured, or contains large particles. Do not shake the pre-filled syringe.</p><p>&nbsp;</p><p>Comprehensive instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Each pre-filled syringe is for single use only.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>